Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 14 | 2022 | 259 | 4.520 |
Why?
|
Genetic Predisposition to Disease | 35 | 2023 | 414 | 3.190 |
Why?
|
Colorectal Neoplasms | 24 | 2023 | 656 | 2.610 |
Why?
|
Polymorphism, Single Nucleotide | 39 | 2023 | 412 | 2.040 |
Why?
|
Early Detection of Cancer | 6 | 2022 | 526 | 1.540 |
Why?
|
Polymorphism, Genetic | 11 | 2015 | 78 | 1.390 |
Why?
|
Humans | 110 | 2023 | 18430 | 1.360 |
Why?
|
Genome-Wide Association Study | 21 | 2023 | 252 | 1.340 |
Why?
|
Middle Aged | 71 | 2021 | 8284 | 1.330 |
Why?
|
Aged | 63 | 2021 | 6417 | 1.330 |
Why?
|
Breast Neoplasms | 12 | 2023 | 1037 | 1.320 |
Why?
|
Case-Control Studies | 47 | 2022 | 1173 | 1.310 |
Why?
|
Biliary Tract Neoplasms | 14 | 2010 | 15 | 1.270 |
Why?
|
Risk Factors | 56 | 2023 | 3449 | 1.260 |
Why?
|
Prostatic Neoplasms | 11 | 2020 | 298 | 1.220 |
Why?
|
Female | 81 | 2023 | 13136 | 1.210 |
Why?
|
Male | 73 | 2021 | 10440 | 1.190 |
Why?
|
Biomarkers, Tumor | 11 | 2021 | 146 | 1.120 |
Why?
|
Fibrocystic Breast Disease | 4 | 2010 | 5 | 1.060 |
Why?
|
Gallstones | 10 | 2010 | 14 | 0.920 |
Why?
|
Tomography, X-Ray Computed | 4 | 2021 | 208 | 0.900 |
Why?
|
Adult | 51 | 2021 | 7910 | 0.880 |
Why?
|
Molecular Epidemiology | 4 | 2021 | 44 | 0.850 |
Why?
|
Genotype | 16 | 2021 | 253 | 0.750 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 19 | 0.720 |
Why?
|
Smoking | 6 | 2020 | 494 | 0.710 |
Why?
|
Patient Compliance | 2 | 2021 | 318 | 0.680 |
Why?
|
Asian Continental Ancestry Group | 8 | 2020 | 90 | 0.660 |
Why?
|
Decision Making | 1 | 2020 | 204 | 0.650 |
Why?
|
Patient Education as Topic | 1 | 2020 | 214 | 0.650 |
Why?
|
Carcinoma | 2 | 2018 | 27 | 0.650 |
Why?
|
Delivery of Health Care | 2 | 2022 | 444 | 0.610 |
Why?
|
Mendelian Randomization Analysis | 7 | 2021 | 24 | 0.610 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 392 | 0.600 |
Why?
|
Ovarian Neoplasms | 3 | 2013 | 50 | 0.550 |
Why?
|
Thyroid Neoplasms | 3 | 2019 | 12 | 0.550 |
Why?
|
Substance Abuse Treatment Centers | 2 | 2011 | 75 | 0.540 |
Why?
|
Quality Improvement | 3 | 2020 | 207 | 0.530 |
Why?
|
Substance-Related Disorders | 3 | 2011 | 439 | 0.530 |
Why?
|
China | 20 | 2010 | 130 | 0.520 |
Why?
|
Aged, 80 and over | 13 | 2020 | 2003 | 0.510 |
Why?
|
Logistic Models | 10 | 2021 | 962 | 0.500 |
Why?
|
Cohort Studies | 14 | 2021 | 2672 | 0.490 |
Why?
|
Metformin | 1 | 2015 | 61 | 0.480 |
Why?
|
Estrogen Receptor alpha | 2 | 2010 | 27 | 0.460 |
Why?
|
MicroRNAs | 3 | 2017 | 17 | 0.450 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2013 | 9 | 0.440 |
Why?
|
Hypoglycemic Agents | 1 | 2015 | 288 | 0.410 |
Why?
|
Cyclooxygenase 2 | 4 | 2020 | 7 | 0.410 |
Why?
|
State Medicine | 1 | 2011 | 6 | 0.400 |
Why?
|
Steroid 17-alpha-Hydroxylase | 3 | 2008 | 16 | 0.400 |
Why?
|
Incidence | 10 | 2020 | 1314 | 0.400 |
Why?
|
Efficiency, Organizational | 1 | 2011 | 36 | 0.400 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 760 | 0.390 |
Why?
|
Carcinogenesis | 3 | 2020 | 9 | 0.390 |
Why?
|
Alleles | 9 | 2020 | 95 | 0.390 |
Why?
|
Risk Assessment | 10 | 2021 | 1143 | 0.380 |
Why?
|
Health | 3 | 2015 | 35 | 0.380 |
Why?
|
Receptors, Androgen | 1 | 2010 | 13 | 0.370 |
Why?
|
Testicular Neoplasms | 5 | 2008 | 11 | 0.370 |
Why?
|
Health Policy | 1 | 2011 | 136 | 0.360 |
Why?
|
Sex Factors | 8 | 2021 | 661 | 0.360 |
Why?
|
European Continental Ancestry Group | 9 | 2021 | 554 | 0.360 |
Why?
|
Diet | 2 | 2021 | 371 | 0.360 |
Why?
|
Breast Density | 2 | 2020 | 31 | 0.350 |
Why?
|
Aspirin | 3 | 2021 | 67 | 0.350 |
Why?
|
Aging | 3 | 2015 | 165 | 0.350 |
Why?
|
Alcohol Drinking | 4 | 2022 | 375 | 0.340 |
Why?
|
Population Surveillance | 6 | 2009 | 271 | 0.340 |
Why?
|
Estradiol Dehydrogenases | 2 | 2008 | 3 | 0.340 |
Why?
|
Liver Neoplasms | 3 | 2007 | 42 | 0.330 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2017 | 55 | 0.330 |
Why?
|
Mass Screening | 5 | 2022 | 690 | 0.330 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2007 | 26 | 0.330 |
Why?
|
Cholesterol Side-Chain Cleavage Enzyme | 1 | 2008 | 1 | 0.320 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 199 | 0.310 |
Why?
|
Selenium | 2 | 2021 | 4 | 0.310 |
Why?
|
Age Factors | 5 | 2021 | 965 | 0.300 |
Why?
|
Risk | 8 | 2022 | 552 | 0.300 |
Why?
|
Glutathione S-Transferase pi | 1 | 2007 | 2 | 0.300 |
Why?
|
Glutathione Transferase | 1 | 2007 | 13 | 0.300 |
Why?
|
Body Mass Index | 8 | 2023 | 974 | 0.300 |
Why?
|
DNA Repair | 4 | 2017 | 10 | 0.290 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 51 | 0.290 |
Why?
|
Gene Expression | 4 | 2022 | 23 | 0.290 |
Why?
|
Folic Acid | 2 | 2022 | 35 | 0.290 |
Why?
|
Endometrial Neoplasms | 3 | 2014 | 39 | 0.280 |
Why?
|
Retrospective Studies | 7 | 2020 | 2550 | 0.280 |
Why?
|
Ethnic Groups | 6 | 2020 | 501 | 0.280 |
Why?
|
Membrane Proteins | 2 | 2006 | 40 | 0.280 |
Why?
|
Neoplasms | 2 | 2022 | 457 | 0.270 |
Why?
|
Nails | 1 | 2005 | 2 | 0.260 |
Why?
|
Macular Degeneration | 2 | 2016 | 19 | 0.260 |
Why?
|
Computational Biology | 2 | 2015 | 28 | 0.260 |
Why?
|
Obesity | 7 | 2023 | 855 | 0.260 |
Why?
|
Feces | 2 | 2020 | 88 | 0.240 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 4 | 2008 | 5 | 0.240 |
Why?
|
Homeodomain Proteins | 2 | 2015 | 16 | 0.230 |
Why?
|
Multifactorial Inheritance | 2 | 2020 | 20 | 0.230 |
Why?
|
United States | 9 | 2020 | 4164 | 0.230 |
Why?
|
Genotyping Techniques | 3 | 2021 | 26 | 0.220 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 16 | 0.220 |
Why?
|
Educational Status | 2 | 2020 | 205 | 0.220 |
Why?
|
Watchful Waiting | 2 | 2019 | 18 | 0.220 |
Why?
|
Transcriptome | 1 | 2023 | 22 | 0.220 |
Why?
|
DNA-Binding Proteins | 4 | 2022 | 31 | 0.220 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2022 | 15 | 0.210 |
Why?
|
Referral and Consultation | 2 | 2021 | 180 | 0.210 |
Why?
|
Adenocarcinoma | 2 | 2017 | 177 | 0.210 |
Why?
|
Genetic Variation | 4 | 2017 | 87 | 0.210 |
Why?
|
Medical Oncology | 1 | 2022 | 32 | 0.210 |
Why?
|
NF-kappa B | 2 | 2022 | 11 | 0.210 |
Why?
|
Surveys and Questionnaires | 4 | 2020 | 1389 | 0.210 |
Why?
|
Carcinoma, Papillary | 1 | 2002 | 3 | 0.200 |
Why?
|
Salicylic Acid | 1 | 2021 | 1 | 0.200 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 68 | 0.200 |
Why?
|
Bilirubin | 2 | 2020 | 30 | 0.200 |
Why?
|
Reproductive History | 1 | 2002 | 18 | 0.200 |
Why?
|
Genomics | 3 | 2020 | 66 | 0.200 |
Why?
|
Mammography | 2 | 2020 | 174 | 0.200 |
Why?
|
Menarche | 1 | 2002 | 30 | 0.200 |
Why?
|
Micronutrients | 1 | 2021 | 9 | 0.190 |
Why?
|
Signal Transduction | 2 | 2018 | 30 | 0.190 |
Why?
|
Health Care Costs | 2 | 2020 | 251 | 0.190 |
Why?
|
Smad7 Protein | 1 | 2021 | 2 | 0.190 |
Why?
|
Metabolome | 1 | 2020 | 1 | 0.190 |
Why?
|
Academic Medical Centers | 1 | 2021 | 31 | 0.190 |
Why?
|
Models, Genetic | 1 | 2020 | 24 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2020 | 4 | 0.180 |
Why?
|
African Americans | 3 | 2020 | 490 | 0.180 |
Why?
|
Immunologic Tests | 1 | 2020 | 6 | 0.180 |
Why?
|
Counseling | 1 | 2022 | 197 | 0.180 |
Why?
|
Genome, Human | 1 | 2020 | 42 | 0.180 |
Why?
|
Fruit | 1 | 2020 | 79 | 0.180 |
Why?
|
Dietary Fiber | 1 | 2020 | 60 | 0.180 |
Why?
|
Vegetables | 1 | 2020 | 87 | 0.180 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 19 | 0.180 |
Why?
|
Arachidonic Acid | 1 | 2020 | 1 | 0.180 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2020 | 5 | 0.180 |
Why?
|
Family Health | 1 | 2010 | 49 | 0.180 |
Why?
|
Adiposity | 1 | 2020 | 67 | 0.180 |
Why?
|
Eicosapentaenoic Acid | 1 | 2020 | 9 | 0.180 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2019 | 11 | 0.180 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2019 | 17 | 0.180 |
Why?
|
Genetic Loci | 2 | 2017 | 60 | 0.170 |
Why?
|
Tobacco Smoking | 1 | 2020 | 20 | 0.170 |
Why?
|
Return to Work | 1 | 2019 | 2 | 0.170 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
Mandatory Programs | 1 | 2009 | 5 | 0.170 |
Why?
|
Multivariate Analysis | 1 | 2021 | 598 | 0.170 |
Why?
|
Health Services | 1 | 2010 | 117 | 0.170 |
Why?
|
Workplace | 1 | 2009 | 36 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2019 | 55 | 0.160 |
Why?
|
Employment | 1 | 2009 | 48 | 0.160 |
Why?
|
Bile Duct Neoplasms | 3 | 2008 | 5 | 0.160 |
Why?
|
Cytochrome P-450 CYP1A1 | 2 | 2009 | 6 | 0.160 |
Why?
|
Women's Health | 1 | 2020 | 207 | 0.160 |
Why?
|
Postmenopause | 1 | 2020 | 267 | 0.160 |
Why?
|
Prostate-Specific Antigen | 2 | 2017 | 77 | 0.160 |
Why?
|
Gene Expression Profiling | 3 | 2023 | 34 | 0.160 |
Why?
|
Healthcare Disparities | 1 | 2020 | 211 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 3 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 5 | 0.150 |
Why?
|
Lymph Nodes | 2 | 2019 | 17 | 0.150 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2017 | 1 | 0.150 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2017 | 2 | 0.150 |
Why?
|
Oncogenes | 1 | 2017 | 1 | 0.150 |
Why?
|
Genes, Tumor Suppressor | 1 | 2017 | 1 | 0.150 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 9 | 0.150 |
Why?
|
Health Services Accessibility | 1 | 2020 | 320 | 0.150 |
Why?
|
Body Size | 2 | 2008 | 31 | 0.150 |
Why?
|
Mutation | 3 | 2023 | 132 | 0.150 |
Why?
|
Young Adult | 3 | 2020 | 2518 | 0.150 |
Why?
|
Registries | 7 | 2019 | 490 | 0.150 |
Why?
|
Breast | 3 | 2023 | 84 | 0.140 |
Why?
|
Odds Ratio | 7 | 2010 | 701 | 0.140 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 157 | 0.140 |
Why?
|
Haplotypes | 7 | 2015 | 43 | 0.140 |
Why?
|
Adenoma | 1 | 2018 | 100 | 0.140 |
Why?
|
Uterine Neoplasms | 2 | 2007 | 12 | 0.140 |
Why?
|
Endometriosis | 2 | 2007 | 4 | 0.140 |
Why?
|
Renin-Angiotensin System | 1 | 2016 | 17 | 0.140 |
Why?
|
HLA-DQ beta-Chains | 1 | 2016 | 2 | 0.130 |
Why?
|
Mutation, Missense | 1 | 2016 | 21 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 50 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2019 | 1269 | 0.130 |
Why?
|
Telomere | 1 | 2015 | 19 | 0.130 |
Why?
|
Phenotype | 3 | 2022 | 148 | 0.130 |
Why?
|
California | 5 | 2020 | 2365 | 0.120 |
Why?
|
Primary Health Care | 1 | 2021 | 848 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 36 | 0.120 |
Why?
|
Adolescent | 3 | 2020 | 3798 | 0.120 |
Why?
|
Gene Frequency | 2 | 2017 | 48 | 0.110 |
Why?
|
Receptors, Interleukin | 1 | 2013 | 4 | 0.110 |
Why?
|
Prognosis | 4 | 2020 | 624 | 0.110 |
Why?
|
Continental Population Groups | 1 | 2015 | 315 | 0.110 |
Why?
|
Alcoholism | 1 | 2017 | 350 | 0.110 |
Why?
|
Urban Population | 2 | 2005 | 124 | 0.110 |
Why?
|
Cooperative Behavior | 1 | 2013 | 102 | 0.110 |
Why?
|
Ibuprofen | 1 | 2012 | 9 | 0.100 |
Why?
|
Microsatellite Instability | 2 | 2023 | 16 | 0.100 |
Why?
|
CpG Islands | 2 | 2023 | 22 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2023 | 16 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 25 | 0.100 |
Why?
|
Gallbladder Neoplasms | 2 | 2010 | 3 | 0.100 |
Why?
|
DNA Methylation | 2 | 2023 | 42 | 0.100 |
Why?
|
Inflammation | 2 | 2008 | 63 | 0.100 |
Why?
|
Chronic Disease | 2 | 2010 | 468 | 0.100 |
Why?
|
beta Carotene | 1 | 2011 | 17 | 0.090 |
Why?
|
Sex Characteristics | 2 | 2015 | 70 | 0.090 |
Why?
|
Cyst Fluid | 1 | 2010 | 1 | 0.090 |
Why?
|
Whole Exome Sequencing | 2 | 2022 | 8 | 0.090 |
Why?
|
Parity | 2 | 2010 | 74 | 0.090 |
Why?
|
Europe | 2 | 2020 | 44 | 0.090 |
Why?
|
Cholelithiasis | 2 | 2007 | 3 | 0.090 |
Why?
|
Liver Cirrhosis | 2 | 2007 | 34 | 0.090 |
Why?
|
Seminoma | 2 | 2007 | 3 | 0.090 |
Why?
|
Reproduction | 1 | 2010 | 12 | 0.090 |
Why?
|
Estrogen Receptor beta | 1 | 2010 | 12 | 0.090 |
Why?
|
Asian Americans | 2 | 2008 | 182 | 0.090 |
Why?
|
Datasets as Topic | 2 | 2020 | 17 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 33 | 0.090 |
Why?
|
Hyperlipidemias | 1 | 2009 | 58 | 0.090 |
Why?
|
Promoter Regions, Genetic | 3 | 2020 | 15 | 0.090 |
Why?
|
Quantitative Trait Loci | 2 | 2022 | 38 | 0.080 |
Why?
|
Lipids | 1 | 2009 | 78 | 0.080 |
Why?
|
Prospective Studies | 3 | 2020 | 1314 | 0.080 |
Why?
|
Age Distribution | 3 | 2008 | 261 | 0.080 |
Why?
|
Hepatitis B Surface Antigens | 2 | 2007 | 12 | 0.080 |
Why?
|
Hormones | 1 | 2009 | 17 | 0.080 |
Why?
|
Aromatase | 1 | 2008 | 10 | 0.080 |
Why?
|
DNA Modification Methylases | 1 | 2008 | 2 | 0.080 |
Why?
|
Tumor Suppressor Proteins | 1 | 2008 | 3 | 0.080 |
Why?
|
DNA Repair Enzymes | 1 | 2008 | 6 | 0.080 |
Why?
|
Lymphoma | 1 | 2008 | 7 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 7 | 0.080 |
Why?
|
Lipid Metabolism | 1 | 2008 | 13 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 28 | 0.080 |
Why?
|
SEER Program | 1 | 2008 | 101 | 0.080 |
Why?
|
Biliary Tract | 1 | 2007 | 2 | 0.080 |
Why?
|
Genetic Pleiotropy | 2 | 2020 | 9 | 0.080 |
Why?
|
Body Height | 1 | 2008 | 62 | 0.080 |
Why?
|
Guaiac | 1 | 2007 | 3 | 0.080 |
Why?
|
Scavenger Receptors, Class A | 1 | 2007 | 2 | 0.080 |
Why?
|
Immunochemistry | 1 | 2007 | 19 | 0.070 |
Why?
|
Prostatic Hyperplasia | 1 | 2007 | 24 | 0.070 |
Why?
|
Feeding Behavior | 2 | 2006 | 168 | 0.070 |
Why?
|
Survival Rate | 2 | 2019 | 269 | 0.070 |
Why?
|
Hepatitis, Viral, Human | 1 | 2007 | 4 | 0.070 |
Why?
|
Liver | 1 | 2007 | 33 | 0.070 |
Why?
|
Fertility | 1 | 2007 | 10 | 0.070 |
Why?
|
Bile Duct Diseases | 1 | 2007 | 1 | 0.070 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2007 | 1 | 0.070 |
Why?
|
Cholangiocarcinoma | 1 | 2007 | 1 | 0.070 |
Why?
|
Denmark | 4 | 2007 | 19 | 0.070 |
Why?
|
Insulin | 1 | 2008 | 208 | 0.070 |
Why?
|
Liver Diseases | 1 | 2007 | 25 | 0.070 |
Why?
|
Metabolic Syndrome | 1 | 2007 | 80 | 0.070 |
Why?
|
Dairy Products | 1 | 2006 | 23 | 0.070 |
Why?
|
Sampling Studies | 1 | 2006 | 55 | 0.070 |
Why?
|
Interviews as Topic | 4 | 2009 | 327 | 0.070 |
Why?
|
Tea | 1 | 2006 | 8 | 0.070 |
Why?
|
Tobacco Smoke Pollution | 1 | 2006 | 34 | 0.070 |
Why?
|
Occult Blood | 1 | 2007 | 167 | 0.070 |
Why?
|
Genetics, Population | 1 | 2005 | 8 | 0.070 |
Why?
|
Puberty | 1 | 2006 | 58 | 0.070 |
Why?
|
DNA Glycosylases | 1 | 2005 | 6 | 0.070 |
Why?
|
Confidence Intervals | 2 | 2006 | 253 | 0.070 |
Why?
|
Hepatitis | 1 | 2005 | 5 | 0.060 |
Why?
|
Leiomyoma | 1 | 2005 | 12 | 0.060 |
Why?
|
Occupations | 1 | 2005 | 16 | 0.060 |
Why?
|
Colposcopy | 1 | 2005 | 4 | 0.060 |
Why?
|
Mothers | 1 | 2006 | 110 | 0.060 |
Why?
|
Cervix Uteri | 1 | 2005 | 5 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2017 | 80 | 0.060 |
Why?
|
Treatment Outcome | 2 | 2017 | 1296 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 321 | 0.060 |
Why?
|
Hemochromatosis | 1 | 2005 | 9 | 0.060 |
Why?
|
San Francisco | 2 | 2002 | 68 | 0.060 |
Why?
|
Adenomatous Polyps | 1 | 2005 | 15 | 0.060 |
Why?
|
Neoplasm Grading | 2 | 2016 | 49 | 0.060 |
Why?
|
Tissue Preservation | 1 | 2004 | 1 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 365 | 0.060 |
Why?
|
Chi-Square Distribution | 3 | 2008 | 160 | 0.060 |
Why?
|
Models, Statistical | 2 | 2010 | 185 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2005 | 127 | 0.060 |
Why?
|
Colonoscopy | 2 | 2020 | 268 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2019 | 747 | 0.050 |
Why?
|
Exome | 1 | 2022 | 25 | 0.050 |
Why?
|
RNA-Binding Proteins | 1 | 2022 | 6 | 0.050 |
Why?
|
Electron Transport Complex IV | 1 | 2022 | 2 | 0.050 |
Why?
|
Linkage Disequilibrium | 2 | 2016 | 39 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 743 | 0.050 |
Why?
|
Contraceptives, Oral | 1 | 2002 | 26 | 0.050 |
Why?
|
Reference Values | 1 | 2002 | 93 | 0.050 |
Why?
|
Plants | 1 | 2001 | 2 | 0.050 |
Why?
|
Estrogens, Non-Steroidal | 1 | 2001 | 3 | 0.050 |
Why?
|
Isoflavones | 1 | 2001 | 14 | 0.050 |
Why?
|
Thorax | 1 | 2021 | 5 | 0.050 |
Why?
|
Continuity of Patient Care | 1 | 2022 | 112 | 0.050 |
Why?
|
Vitamin B 12 | 1 | 2021 | 15 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2015 | 24 | 0.050 |
Why?
|
Waist-Hip Ratio | 1 | 2020 | 23 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 1 | 0.050 |
Why?
|
Lung | 1 | 2021 | 62 | 0.050 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 3 | 0.050 |
Why?
|
Marketing of Health Services | 1 | 2020 | 4 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2021 | 88 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2020 | 17 | 0.050 |
Why?
|
Medically Uninsured | 1 | 2020 | 61 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1 | 0.050 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 1 | 0.050 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2020 | 1 | 0.050 |
Why?
|
Voltage-Gated Sodium Channel beta-1 Subunit | 1 | 2020 | 1 | 0.050 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 1 | 2020 | 1 | 0.050 |
Why?
|
Databases, Genetic | 1 | 2020 | 10 | 0.040 |
Why?
|
ATPases Associated with Diverse Cellular Activities | 1 | 2020 | 3 | 0.040 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2020 | 69 | 0.040 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2019 | 3 | 0.040 |
Why?
|
Mutation Rate | 1 | 2019 | 3 | 0.040 |
Why?
|
Whole Genome Sequencing | 1 | 2019 | 7 | 0.040 |
Why?
|
Protective Factors | 1 | 2020 | 33 | 0.040 |
Why?
|
United Kingdom | 1 | 2019 | 32 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
Minority Groups | 1 | 2020 | 105 | 0.040 |
Why?
|
Medical History Taking | 1 | 2019 | 37 | 0.040 |
Why?
|
Matched-Pair Analysis | 1 | 2019 | 11 | 0.040 |
Why?
|
Social Class | 1 | 2020 | 125 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2022 | 228 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 29 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2019 | 6 | 0.040 |
Why?
|
Age of Onset | 1 | 2019 | 82 | 0.040 |
Why?
|
B7-H1 Antigen | 1 | 2019 | 2 | 0.040 |
Why?
|
Immunotherapy | 1 | 2019 | 7 | 0.040 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2019 | 5 | 0.040 |
Why?
|
Pilot Projects | 1 | 2020 | 237 | 0.040 |
Why?
|
Insurance Coverage | 1 | 2020 | 136 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2019 | 29 | 0.040 |
Why?
|
Family | 1 | 2010 | 120 | 0.040 |
Why?
|
Propensity Score | 1 | 2019 | 94 | 0.040 |
Why?
|
Medicaid | 1 | 2020 | 211 | 0.040 |
Why?
|
RNA, Long Noncoding | 1 | 2018 | 5 | 0.040 |
Why?
|
Hispanic Americans | 2 | 2017 | 428 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2020 | 199 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 333 | 0.040 |
Why?
|
Cancer Survivors | 1 | 2019 | 89 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2019 | 337 | 0.040 |
Why?
|
Introns | 2 | 2008 | 10 | 0.040 |
Why?
|
Homozygote | 1 | 2017 | 14 | 0.040 |
Why?
|
Health Status | 1 | 2010 | 328 | 0.040 |
Why?
|
Databases, Factual | 1 | 2019 | 327 | 0.040 |
Why?
|
Korea | 2 | 2008 | 9 | 0.040 |
Why?
|
Cells, Cultured | 1 | 2017 | 11 | 0.040 |
Why?
|
Life Style | 1 | 2019 | 342 | 0.040 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2017 | 4 | 0.040 |
Why?
|
Alcohol Dehydrogenase | 1 | 2017 | 5 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 131 | 0.040 |
Why?
|
Regression Analysis | 2 | 2008 | 319 | 0.040 |
Why?
|
Disease Progression | 1 | 2018 | 271 | 0.040 |
Why?
|
Survival Analysis | 1 | 2017 | 226 | 0.040 |
Why?
|
Prostate | 1 | 2017 | 29 | 0.040 |
Why?
|
Carboplatin | 1 | 2016 | 7 | 0.040 |
Why?
|
Bevacizumab | 1 | 2016 | 8 | 0.030 |
Why?
|
Paclitaxel | 1 | 2016 | 9 | 0.030 |
Why?
|
African Continental Ancestry Group | 1 | 2017 | 166 | 0.030 |
Why?
|
Poland | 2 | 2007 | 3 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2015 | 9 | 0.030 |
Why?
|
INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2015 | 23 | 0.030 |
Why?
|
Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
Quality Control | 1 | 2015 | 48 | 0.030 |
Why?
|
Pedigree | 1 | 2015 | 58 | 0.030 |
Why?
|
Self Report | 1 | 2017 | 256 | 0.030 |
Why?
|
Phylogeny | 1 | 2015 | 14 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 23 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2015 | 399 | 0.030 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2010 | 567 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 20 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 13 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 27 | 0.030 |
Why?
|
Child | 1 | 2010 | 2571 | 0.030 |
Why?
|
Pregnancy | 2 | 2010 | 1516 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 83 | 0.030 |
Why?
|
Prevalence | 1 | 2015 | 911 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 114 | 0.020 |
Why?
|
Xeroderma Pigmentosum Group A Protein | 1 | 2011 | 1 | 0.020 |
Why?
|
DNA Ligase ATP | 1 | 2011 | 2 | 0.020 |
Why?
|
DNA Ligases | 1 | 2011 | 2 | 0.020 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2011 | 2 | 0.020 |
Why?
|
DNA Helicases | 1 | 2011 | 2 | 0.020 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2011 | 4 | 0.020 |
Why?
|
Endonucleases | 1 | 2011 | 3 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2011 | 11 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 20 | 0.020 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2009 | 1 | 0.020 |
Why?
|
Apolipoproteins B | 1 | 2009 | 8 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2009 | 9 | 0.020 |
Why?
|
Demography | 1 | 2010 | 108 | 0.020 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2009 | 12 | 0.020 |
Why?
|
DNA | 1 | 2009 | 25 | 0.020 |
Why?
|
Breast Self-Examination | 1 | 2008 | 6 | 0.020 |
Why?
|
Cyclin H | 1 | 2008 | 1 | 0.020 |
Why?
|
Cyclins | 1 | 2008 | 2 | 0.020 |
Why?
|
Japan | 1 | 2008 | 14 | 0.020 |
Why?
|
Philippines | 1 | 2008 | 22 | 0.020 |
Why?
|
Vietnam | 1 | 2008 | 34 | 0.020 |
Why?
|
Hydro-Lyases | 1 | 2008 | 1 | 0.020 |
Why?
|
Peroxisomal Multifunctional Protein-2 | 1 | 2008 | 1 | 0.020 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2008 | 6 | 0.020 |
Why?
|
Retinoic Acid Receptor alpha | 1 | 2008 | 1 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2008 | 2 | 0.020 |
Why?
|
PPAR gamma | 1 | 2008 | 10 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2008 | 21 | 0.020 |
Why?
|
Bile Acids and Salts | 1 | 2007 | 3 | 0.020 |
Why?
|
Organ Size | 1 | 2007 | 16 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2007 | 5 | 0.020 |
Why?
|
Thyroid Diseases | 1 | 2007 | 2 | 0.020 |
Why?
|
Gallbladder Diseases | 1 | 2007 | 2 | 0.020 |
Why?
|
5' Untranslated Regions | 1 | 2007 | 1 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2007 | 2 | 0.020 |
Why?
|
Exons | 1 | 2007 | 10 | 0.020 |
Why?
|
Somatomedins | 1 | 2007 | 5 | 0.020 |
Why?
|
Abdominal Fat | 1 | 2007 | 15 | 0.020 |
Why?
|
Erythrocytes | 1 | 2007 | 7 | 0.020 |
Why?
|
DNA, Viral | 1 | 2007 | 17 | 0.020 |
Why?
|
Leptin | 1 | 2007 | 30 | 0.020 |
Why?
|
Cholesterol | 1 | 2007 | 112 | 0.020 |
Why?
|
Sigmoidoscopy | 1 | 2007 | 67 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2007 | 22 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 53 | 0.020 |
Why?
|
Cholangitis | 1 | 2007 | 1 | 0.020 |
Why?
|
Cholecystolithiasis | 1 | 2007 | 1 | 0.020 |
Why?
|
Choledocholithiasis | 1 | 2007 | 1 | 0.020 |
Why?
|
Liver Diseases, Alcoholic | 1 | 2007 | 5 | 0.020 |
Why?
|
Lymphotoxin-alpha | 1 | 2007 | 2 | 0.020 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2007 | 4 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2007 | 19 | 0.020 |
Why?
|
Maryland | 1 | 2006 | 15 | 0.020 |
Why?
|
Hepatitis B | 1 | 2007 | 43 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2006 | 2 | 0.020 |
Why?
|
Maternal Behavior | 1 | 2006 | 13 | 0.020 |
Why?
|
Genetic Markers | 1 | 2006 | 28 | 0.020 |
Why?
|
Computer Simulation | 1 | 2006 | 85 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2006 | 115 | 0.020 |
Why?
|
Mortality | 1 | 2006 | 123 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2006 | 119 | 0.020 |
Why?
|
Artifacts | 1 | 2005 | 3 | 0.020 |
Why?
|
Chemoprevention | 1 | 2005 | 12 | 0.020 |
Why?
|
Biopsy | 1 | 2005 | 75 | 0.020 |
Why?
|
Heterozygote | 1 | 2005 | 29 | 0.020 |
Why?
|
Iron | 1 | 2005 | 17 | 0.020 |
Why?
|
Algorithms | 1 | 2006 | 241 | 0.020 |
Why?
|
Epitopes | 1 | 2004 | 4 | 0.010 |
Why?
|
Paraffin Embedding | 1 | 2004 | 6 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2004 | 12 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2004 | 46 | 0.010 |
Why?
|
Receptor, ErbB-2 | 1 | 2004 | 48 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2004 | 52 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2004 | 58 | 0.010 |
Why?
|
Research Design | 1 | 2006 | 402 | 0.010 |
Why?
|
Time Factors | 1 | 2006 | 1136 | 0.010 |
Why?
|
Hypertension | 1 | 2007 | 524 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2007 | 530 | 0.010 |
Why?
|
Phytoestrogens | 1 | 2001 | 7 | 0.010 |
Why?
|
Plant Preparations | 1 | 2001 | 6 | 0.010 |
Why?
|